Nuvation Bio And 2 Top Penny Stocks To Watch

Simply Wall St · 2d ago

Artificial intelligence funding keeps drawing headlines after Anthropic filed for what could be the biggest IPO ever, and that spotlight on high priced tech has many investors hunting for cheaper ways to plug into future growth stories. That is where lower priced, financially sound small caps come in. This article highlights three budget friendly stocks from a quality focused penny universe that combine disciplined balance sheets with efforts to pursue higher growth.

The three stocks highlighted here offer a compelling starting point if you want exposure to lower risk early-stage businesses with an emphasis on stronger financial footing. However, if you want the absolute best, these 7 elite penny stocks are the cream of the crop.

Nuvation Bio (NUVB)

Nuvation Bio fits within the Financially Fit Penny Stocks theme because its oncology pipeline is already in the clinic, giving this smaller-cap biopharma a concrete shot at durable cancer treatments rather than just early lab concepts.

Nuvation Bio is a clinical-stage cancer drug developer built around targeted therapies like IBTROZI and safusidenib, generating US$169.9 million from oncology development activities and carrying a market value of about US$1.6b.

"The updated U.S. IBTROZI label that now includes a nearly 50 month median duration of response in TKI naïve ROS1 positive non small cell lung cancer supports a chronic like treatment profile that can lengthen revenue recognition per patient and support higher long term earnings quality."

The key factor ahead for Nuvation Bio is how one long-cycle oncology driver ultimately influences both pricing power and margin potential.

That long-cycle driver is the real story here, and the full narrative for Nuvation Bio unpacks how pricing power, trial risk and capital allocation could all be quietly shifting in Nuvation Bio's favor.

NYSE:NUVB Earnings & Revenue Growth as at Oct 2026
NYSE:NUVB Earnings & Revenue Growth as at Oct 2026

Grab Holdings (GRAB)

Grab Holdings ties into the Financially Fit Penny Stocks theme through GrabFin, its regulated digital lending and payments arm. This is layered on top of a superapp that runs mobility, deliveries and advertising across Southeast Asia, creating a fuller commercial funnel than a pure fintech start-up.

Grab runs a superapp across eight Southeast Asian markets, with most income coming from Deliveries at about US$2.0b and Mobility at roughly US$1.3b. Financial Services such as GrabFin adds around US$430 million, supporting a roughly US$11.4b market cap.

"Financial Services may eventually become Grab's second economic engine. Revenue there increased 59%, while the segment's adjusted EBITDA loss narrowed from $26 million to $15 million."

The real swing factor now is whether a quieter shift inside this lending arm can steadily reshape group-level cash generation and resilience.

That quieter shift is exactly what the full narrative for Grab Holdings unpacks, revealing how lending economics, capital discipline and competition could be quietly reshaping the long term trajectory of Grab Holdings.

NasdaqGS:GRAB Revenue & Expenses Breakdown as at Oct 2026
NasdaqGS:GRAB Revenue & Expenses Breakdown as at Oct 2026

Aurora Innovation (AUR)

Aurora Innovation gives this Financially Fit Penny Stocks list a pure play on self-driving freight, with the Aurora Driver platform aimed at turning early commercial pilots into a larger, recurring software and services model over time.

Aurora Innovation focuses on Aurora Driver, a self-driving hardware, software and data platform for freight partners, currently generating about US$5 million from Computer Services in the United States and carrying a market value near US$9.6b.

The appeal for this screener is that Aurora Innovation uses the Aurora Driver as its main bet on autonomy, while still keeping a tight focus on one core trucking use case that can be measured in real operating miles rather than only lab tests.

"Aurora Innovation is currently operating driverless trucks in daily commercial freight without safety drivers and has accumulated more than 500,000 commercial miles, which can position the company as a preferred partner for carriers that want proven autonomy at scale and support higher subscription style revenue as additional fleets seek similar deployment."

What matters now is how one still unresolved funding and rollout challenge shapes the point where all that scale starts to lift margins.

That inflection point is exactly where the full narrative for Aurora Innovation pulls ahead, explaining how funding risk, rollout timing and freight partnerships could move Aurora Innovation from pilot momentum to scaled economics.

NasdaqGS:AUR Earnings & Revenue Growth as at Oct 2026
NasdaqGS:AUR Earnings & Revenue Growth as at Oct 2026

Seeking Fresh Alternatives Before They Fly

New leaders often break out quietly, then move fast once the crowd catches on. Scan these fresh ideas while the data is sharp and under the radar for now, and consider them while they are still less widely followed.